Keith A. Goldan serves as the Chief Financial Officer at Syndax Pharmaceuticals Inc., a position he has held since joining the company in 2015. With an extensive background in financial management within the biopharmaceutical industry, Goldan has been instrumental in guiding Syndax through various stages of growth and development. Prior to Syndax, he held the position of CFO at Lev Pharmaceuticals, where he played a key role in the company's successful acquisition by ViroPharma for approximately $640 million. His strategic financial planning and execution skills have been crucial in navigating Syndax's financial landscape, ensuring the company's stability and growth. Goldan's career also includes significant roles at other notable companies within the industry. He served as Vice President of Finance at OSI Pharmaceuticals, where he was part of the team that led the company through its acquisition by Astellas Pharma for $4.0 billion. His experience extends to working at Ernst & Young LLP, where he began his career as a Certified Public Accountant. This diverse experience has equipped him with a deep understanding of financial operations and corporate strategy, making him a valuable asset to Syndax. At Syndax, Goldan oversees all aspects of the company's financial strategy, including budgeting, forecasting, and investor relations, ensuring that the company remains on a solid financial footing as it advances its pipeline of innovative cancer therapies. In his role as CFO, Keith A. Goldan has been pivotal in securing funding and managing resources to support Syndax's clinical trials and research initiatives. His leadership has been crucial in building strong relationships with investors and stakeholders, which has facilitated the company's ability to raise capital effectively. Under his guidance, Syndax has successfully completed several financing rounds, enabling the company to advance its lead product candidates through clinical development. Goldan's strategic vision and financial acumen continue to drive Syndax forward as it strives to bring new treatment options to patients with cancer.